Pharmacologic-Augmented Treatments

doi:10.1017/9781108235655.020

19 - Pharmacologic-Augmented Treatments

from Part II - Obsessive-Compulsive Disorder

Published online by Cambridge University Press: 12 April 2019

Sophie C. Schneider and

Eric A. Storch

Edited by

Lara J. Farrell ,

Thomas H. Ollendick and

Peter Muris

Show author details

Lara J. Farrell: Affiliation:
Griffith University, Queensland
Thomas H. Ollendick: Affiliation:
Virginia Polytechnic Institute and State University
Peter Muris: Affiliation:
Universiteit Maastricht, Netherlands

Book contents

Get access

Type: Chapter
Information: Innovations in CBT for Childhood Anxiety, OCD, and PTSD
Improving Access and Outcomes
, pp. 407 - 427

DOI: https://doi.org/10.1017/9781108235655.020 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Andersson, E., Hedman, E., Enander, J. M., Radu Djurfeldt, D., Ljotsson, B., Cervenka, S.,… Ruck, C. (2015). D-cycloserine vs placebo as adjunct to cognitive behavioral therapy for obsessive-compulsive disorder and interaction with antidepressants: A randomized clinical trial. JAMA Psychiatry, 72(7), 659–667. doi:10.1001/jamapsychiatry.2015.0546CrossRef Google Scholar PubMed

Bloch, M. H., & Storch, E. A. (2015). Assessment and management of treatment-refractory obsessive-compulsive disorder in children. Journal of the American Academy of Child and Adolescent Psychiatry, 54(4), 251–262. doi:10.1016/j.jaac.2015.01.011CrossRef Google Scholar PubMed

Bürkner, P.-C., Bittner, N., Holling, H., & Buhlmann, U. (2017). D-cycloserine augmentation of behavior therapy for anxiety and obsessive-compulsive disorders: A meta-analysis. PloS One, 12(3), e0173660. doi:10.1371/journal.pone.0173660CrossRef Google Scholar PubMed

Bussing, R., Reid, A. M., McNamara, J. P. H., Meyer, J. M., Guzick, A. G., Mason, D. M.,… Murphy, T. K. (2015). A pilot study of actigraphy as an objective measure of SSRI activation symptoms: Results from a randomized placebo controlled psychopharmacological treatment study. Psychiatry Research, 225(3), 440–445. doi:10.1016/j.psychres.2014.11.070CrossRef Google Scholar PubMed

Caporino, N. E., & Storch, E. A. (2016). Personalizing the treatment of pediatric obsessive-compulsive disorder: Evidence for predictors and moderators of treatment outcomes. Current Behavioral Neuroscience Reports, 3(1), 73–85. doi:10.1007/s40473-016–0066-5CrossRef Google Scholar

Chasson, G. S., Buhlmann, U., Tolin, D. F., Rao, S. R., Reese, H. E., Rowley, T.,… Wilhelm, S. (2010). Need for speed: Evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine. Behaviour Research and Therapy, 48(7), 675–679. doi:10.1016/j.brat.2010.03.007CrossRef Google Scholar PubMed

Davis, M., Ressler, K., Rothbaum, B. O., & Richardson, R. (2006). Effects of D-Cycloserine on extinction: Translation from preclinical to clinical work. Biological Psychiatry, 60(4), 369–375. doi:10.1016/j.biopsych.2006.03.084CrossRef Google Scholar PubMed

Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2013). Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: A meta-analysis of double-blind, randomized, placebo-controlled trials. International Journal of Neuropsychopharmacology, 16(3), 557–574. doi:10.1017/s1461145712000740CrossRef Google Scholar PubMed

Farrell, L. J., Waters, A. M., Boschen, M. J., Hattingh, L., McConnell, H., Milliner, E. L.,… Storch, E. A. (2013). Difficult-to-treat pediatric obsessive-compulsive disorder: Feasibility and preliminary results of a randomized pilot trial of d-cycloserine-augmented behavior therapy. Depression and Anxiety, 30(8), 723–731. doi:10.1002/da.22132CrossRef Google Scholar PubMed

Franklin, M. E., Kratz, H. E., Freeman, J. B., Ivarsson, T., Heyman, I., Sookman, D.,… March, J. (2015). Cognitive-behavioral therapy for pediatric obsessive-compulsive disorder: Empirical review and clinical recommendations. Psychiatry Research, 227(1), 78–92. doi:10.1016/j.psychres.2015.02.009CrossRef Google Scholar PubMed

Franklin, M. E., Sapyta, J., Freeman, J. B., Khanna, M., Compton, S., Almirall, D.,… March, J. S. (2011). Cognitive-behavior therapy augmentation of pharmacotherapy in pediatric obsessive compulsive disorder: The pediatric OCD treatment study II (POTS II) randomized, controlled trial. JAMA, 306(11), 1224–1232. doi:10.1001/jama.2011.1344CrossRef Google Scholar PubMed

Garcia, A. M., Sapyta, J. J., Moore, P. S., Freeman, J. B., Franklin, M. E., March, J. S., & Foa, E. B. (2010). Predictors and moderators of treatment outcome in the pediatric obsessive compulsive treatment study (POTS I). Journal of the American Academy of Child and Adolescent Psychiatry, 49(10), 1024–1033. doi:10.1016/j.jaac.2010.06.013CrossRef Google Scholar PubMed

Geller, D. A., March, J., & AACAP Committee on Quality Issues. (2012). Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 51(1), 98–113. doi:10.1016/j.jaac.2011.09.019Google Scholar

Goodman, W. K., Murphy, T. K., & Storch, E. A. (2007). Risk of adverse behavioral effects with pediatric use of antidepressants. Psychopharmacology, 191(1), 87–96. doi:10.1007/s00213-006–0642-6CrossRef Google Scholar PubMed

Grabb, M. C., & Gobburu, J. V. S. (2017). Challenges in developing drugs for pediatric CNS disorders: A focus on psychopharmacology. Progress in Neurobiology, 152, 38–57. doi:10.1016/j.pneurobio.2016.05.003CrossRef Google Scholar PubMed

Graham, B. M., Callaghan, B. L., & Richardson, R. (2014). Bridging the gap: Lessons we have learnt from the merging of psychology and psychiatry for the optimisation of treatments for emotional disorders. Behaviour Research and Therapy, 62, 3–16. doi:10.1016/j.brat.2014.07.012CrossRef Google Scholar PubMed

Gu, W., Storch, E. A., Zhao, Q., Xu, T., & Wang, Z. (2017). Effects of D-cycloserine augmentation on cognitive behavioral therapy in patients with obsessive-compulsive disorder: A systematic review and meta-analysis. Journal of Obsessive-Compulsive and Related Disorders, 13, 24–29. doi:10.1016/j.jocrd.2017.03.001CrossRef Google Scholar

Hammad, T. A., Laughren, T., & Racoosin, J. (2006). Suicidality in pediatric patients treated with antidepressant drugs. Archives of General Psychiatry, 63(3), 332–339. doi:10.1001/archpsyc.63.3.332CrossRef Google Scholar PubMed

Hilt, R. J., Chaudhari, M., Bell, J. F., Wolf, C., Koprowicz, K., & King, B. H. (2014). Side effects from use of one or more psychiatric medications in a population-based sample of children and adolescents. Journal of Child and Adolescent Psychopharmacology, 24(2), 83–89. doi:10.1089/cap.2013.0036CrossRef Google Scholar PubMed

Hofmann, S. G., Otto, M. W., Pollack, M. H., & Smits, J. A. (2015). d-Cycloserine augmentation of cognitive behavioral therapy for anxiety disorders: An update. Current Psychiatry Reports, 17(1), 532. doi:10.1007/s11920-014–0532-2CrossRef Google Scholar PubMed

Ivarsson, T., Skarphedinsson, G., Kornør, H., Axelsdottir, B., Biedilæ, S., Heyman, I.,… March, J. (2015). The place of and evidence for serotonin reuptake inhibitors (SRIs) for obsessive compulsive disorder (OCD) in children and adolescents: Views based on a systematic review and meta-analysis. Psychiatry Research, 227(1), 93–103. doi:10.1016/j.psychres.2015.01.015CrossRef Google Scholar PubMed

Kim, J. H., & Richardson, R. (2010). New findings on extinction of conditioned fear early in development: Theoretical and clinical implications. Biological Psychiatry, 67(4), 297–303. doi:10.1016/j.biopsych.2009.09.003CrossRef Google Scholar PubMed

Lewin, A. B., McGuire, J. F., Murphy, T. K., & Storch, E. A. (2014). Editorial perspective: The importance of considering parent’s preferences when planning treatment for their children – the case of childhood obsessive-compulsive disorder. Journal of Child Psychology and Psychiatry, 55(12), 1314–1316. doi:10.1111/jcpp.12344CrossRef Google Scholar

Lewin, A. B., Peris, T. S., Lindsey Bergman, R., McCracken, J. T., & Piacentini, J. (2011). The role of treatment expectancy in youth receiving exposure-based CBT for obsessive compulsive disorder. Behaviour Research and Therapy, 49(9), 536–543. doi:10.1016/j.brat.2011.06.001CrossRef Google Scholar PubMed

Lewin, A. B., Piacentini, J., De Nadai, A. S., Jones, A. M., Peris, T. S., Geffken, G. R., … Storch, E. A. (2014). Defining clinical severity in pediatric obsessive-compulsive disorder. Psychological Assessment, 26(2), 679–684. doi:10.1037/a0035174CrossRef Google Scholar PubMed

March, J. S., Franklin, M. E., Leonard, H., Garcia, A., Moore, P., Freeman, J., & Foa, E. (2007). Tics moderate treatment outcome with sertraline but not cognitive-behavior therapy in pediatric obsessive-compulsive disorder. Biological Psychiatry, 61(3), 344–347. doi:10.1016/j.biopsych.2006.09.035CrossRef Google Scholar

Maron, E., & Nutt, D. (2015). Biological predictors of pharmacological therapy in anxiety disorders. Dialogues in Clinical Neuroscience, 17(3), 305–317.CrossRef Google Scholar PubMed

Masi, G., Pfanner, C., Millepiedi, S., & Berloffa, S. (2010). Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder. Journal of Clinical Psychopharmacology, 30(6), 688–693. doi:10.1097/JCP.0b013e3181fab7b1CrossRef Google Scholar PubMed

Mataix-Cols, D., de la Cruz, Fernandez, Monzani, L., Rosenfield, B., Andersson, D., Pérez-Vigil, E., A.,… the DCS Anxiety Consortium. (2017). D-cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: A systematic review and meta-analysis of individual participant data. JAMA Psychiatry, 74(5), 501–510. doi:10.1001/jamapsychiatry.2016.3955CrossRef Google Scholar PubMed

Mataix-Cols, D., Turner, C. M., Monzani, B., Isomura, K., Murphy, C., Krebs, G., & Heyman, I. (2014). Cognitive-behavioural therapy with post-session D-cycloserine augmentation for paediatric obsessive-compulsive disorder: Pilot randomised controlled trial. British Journal of Psychiatry, 204(1), 77–78. doi:10.1192/bjp.bp.113.126284CrossRef Google Scholar PubMed

McGuire, J. F., Lewin, A. B., & Storch, E. A. (2014). Enhancing exposure therapy for anxiety disorders, obsessive compulsive disorder, and posttraumatic stress disorder. Expert Review of Neurotherapeutics, 14(8), 893–910. doi:10.1586/14737175.2014.934677CrossRef Google Scholar

McGuire, J. F., Piacentini, J., Lewin, A. B., Brennan, E. A., Murphy, T. K., & Storch, E. A. (2015). A meta-analysis of cognitive behavior therapy and medication for child obsessive–compulsive disorder: Moderators of treatment efficacy, response, and remission. Depression and Anxiety, 32(8), 580–593. doi:10.1002/da.22389CrossRef Google Scholar PubMed

Neziroglu, F., Yaryura-Tobias, J. A., Walz, J., & McKay, D. (2000). The effect of fluvoxamine and behavior therapy on children and adolescents with obsessive-compulsive disorder. Journal of Child and Adolescent Psychopharmacology, 10(4), 295–306. doi:10.1089/cap.2000.10.295CrossRef Google Scholar PubMed

Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008). A meta-analysis of d-cycloserine and the facilitation of fear extinction and exposure therapy. Biological Psychiatry, 63(12), 1118–1126. doi:10.1016/j.biopsych.2008.01.012CrossRef Google Scholar PubMed

O’Neill, J., Piacentini, J., Chang, S., Ly, R., Lai, T. M., Armstrong, C. C., … Nurmi, E. L. (2017). Glutamate in pediatric obsessive-compulsive disorder and response to cognitive-behavioral therapy: Randomized clinical trial. Neuropsychopharmacology, 42, 2414–2422. doi:10.1038/npp.2017.77CrossRef Google Scholar PubMed

Ori, R., Amos, T., Bergman, H., Soares-Weiser, K., Ipser, J. C., & Stein, D. J. (2015). Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders. Cochrane Database of Systematic Reviews (5), Cd007803. doi:10.1002/14651858.CD007803.pub2Google Scholar

Öst, L.-G., Riise, E. N., Wergeland, G. J., Hansen, B., & Kvale, G. (2016). Cognitive behavioral and pharmacological treatments of OCD in children: A systematic review and meta-analysis. Journal of Anxiety Disorders, 43, 58–69. doi:10.1016/j.janxdis.2016.08.003CrossRef Google Scholar PubMed

Otto, M. W., Kredlow, M. A., Smits, J. A. J., Hofmann, S. G., Tolin, D. F., de Kleine, R. A.,… Pollack, M. H. (2016). Enhancement of psychosocial treatment with d-cycloserine: Models, moderators, and future directions. Biological Psychiatry, 80(4), 274–283. doi:10.1016/j.biopsych.2015.09.007CrossRef Google Scholar PubMed

Otto, M. W., McHugh, R. K., & Kantak, K. M. (2010). Combined pharmacotherapy and cognitive-behavioral therapy for anxiety disorders: Medication effects, glucocorticoids, and attenuated treatment outcomes. [Clinical psychology : a publication of the Division of Clinical Psychology of the American Psychological Association]. Clinical Psychology, 17(2), 91–103. doi:10.1111/j.1468–2850.2010.01198.xGoogle Scholar PubMed

Pittenger, C. (2015a). Glutamate modulators in the treatment of obsessive-compulsive disorder. Psychiatric Annals, 45(6), 308–315. doi:10.3928/00485713–20150602-06CrossRef Google Scholar PubMed

Pittenger, C. (2015b). Glutamatergic agents for OCD and related disorders. Current Treatment Options in Psychiatry, 2(3), 271–283. doi:10.1007/s40501-015–0051-8CrossRef Google Scholar PubMed

Pontoski, K. E., & Heimberg, R. G. (2010). The myth of the superiority of concurrent combined treatments for anxiety disorders. Clinical Psychology: Science and Practice, 17(2), 107–111. doi:10.1111/j.1468–2850.2010.01200.xGoogle Scholar

Rapee, R. M., Jones, M. P., Hudson, J. L., Mahli, G. S., Lyneham, H. J., & Schneider, S. C. (2016). d-Cycloserine does not enhance the effects of in-vivo exposure among young people with broad-based anxiety disorders. Behaviour Research and Therapy, 87, 225–231. doi:10.1016/j.brat.2016.10.004CrossRef Google Scholar

Reid, A. M., McNamara, J. P. H., Murphy, T. K., Guzick, A. G., Storch, E. A., Geffken, G. R., & Bussing, R. (2015). Side-effects of SSRIs disrupt multimodal treatment for pediatric OCD in a randomized-controlled trial. Journal of Psychiatric Research, 71, 140–147. doi:10.1016/j.jpsychires.2015.10.006CrossRef Google Scholar PubMed

Rief, W., Barsky, A. J., Bingel, U., Doering, B. K., Schwarting, R., Wöhr, M., & Schweiger, U. (2016). Rethinking psychopharmacotherapy: The role of treatment context and brain plasticity in antidepressant and antipsychotic interventions. Neuroscience and Biobehavioral Reviews, 60, 51–64. doi:10.1016/j.neubiorev.2015.11.008CrossRef Google Scholar PubMed

Scahill, L., Riddle, M. A., McSwiggin-Hardin, M., Ort, S. I., King, R. A., Goodman, W. K.,… Leckman, J. F. (1997). Children’s Yale-Brown Obsessive Compulsive Scale: Reliability and validity. Journal of the American Academy of Child and Adolescent Psychiatry, 36(6), 844–852. doi:10.1097/00004583–199706000-00023CrossRef Google Scholar PubMed

Simpson, H., Foa, E. B., Liebowitz, M. R., & et al. (2013). Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: A randomized clinical trial. JAMA Psychiatry, 70(11), 1190–1199. doi:10.1001/jamapsychiatry.2013.1932CrossRef Google Scholar PubMed

Singewald, N., Schmuckermair, C., Whittle, N., Holmes, A., & Ressler, K. J. (2015). Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharmacology and Therapeutics, 149, 150–190. doi:10.1016/j.pharmthera.2014.12.004CrossRef Google Scholar PubMed

Skarphedinsson, G., Weidle, B., Thomsen, P. H., Dahl, K., Torp, N. C., Nissen, J. B.,… Ivarsson, T. (2015). Continued cognitive-behavior therapy versus sertraline for children and adolescents with obsessive–compulsive disorder that were non-responders to cognitive-behavior therapy: A randomized controlled trial. European Child and Adolescent Psychiatry, 24(5), 591–602. doi:10.1007/s00787-014–0613-0CrossRef Google Scholar PubMed

Smits, J. A. J., Rosenfield, D., Otto, M. W., Powers, M. B., Hofmann, S. G., Telch, M. J.,… Tart, C. D. (2013). D-Cycloserine enhancement of fear extinction is specific to successful exposure sessions: Evidence from the treatment of height phobia. Biological Psychiatry, 73(11), 1054–1058. doi:10.1016/j.biopsych.2012.12.009CrossRef Google Scholar PubMed

Stewart, S. E., & Stachon, A. C. (2014). Pharmacotherapy for obsessive-compulsive and related disorders among children and adolescents. In Storch, E. A. & McKay, D. E. (eds.), Obsessive-compulsive disorder and its spectrum: A life-span approach (pp. 293–316). Washington, DC: American Psychological Association.CrossRef Google Scholar

Storch, E. A., Bussing, R., Small, B. J., Geffken, G. R., McNamara, J. P., Rahman, O.,… Murphy, T. K. (2013). Randomized, placebo-controlled trial of cognitive-behavioral therapy alone or combined with sertraline in the treatment of pediatric obsessive–compulsive disorder. Behaviour Research and Therapy, 51(12), 823–829. doi:10.1016/j.brat.2013.09.007CrossRef Google Scholar PubMed

Storch, E. A., McKay, D., Reid, J., Geller, D., Goodman, W., Lewin, A., & Murphy, T. (2010). D-Cycloserine augmentation of cognitive-behavioral therapy: Directions for pilot research in pediatric obsessive-compulsive disorder. Child and Youth Care Forum, 39(2), 101–112. doi:10.1007/s10566-010–9094-6CrossRef Google Scholar

Storch, E. A., Wilhelm, S., Sprich, S., Henin, A., Micco, J., Small, B. J.,… Geller, D. A. (2016). Efficacy of augmentation of cognitive behavior therapy with weight-adjusted d-cycloserine vs placebo in pediatric obsessive-compulsive disorder: A randomized clinical trial. JAMA Psychiatry, 73(8), 779–788. doi:10.1001/jamapsychiatry.2016.1128CrossRef Google Scholar PubMed

Sulkowski, M. L., Geller, D. A., Lewin, A. B., Murphy, T. K., Mittelman, A., Brown, A., & Storch, E. A. (2014). The future of D-Cycloserine and other cognitive modifiers in obsessive-compulsive and related disorders. Current Psychiatry Reviews, 10(4), 317–324. doi:10.2174/1573400510666140619224942CrossRef Google Scholar PubMed

The Pediatric OCD Treatment Study (POTS) Team. (2004). Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: The pediatric OCD treatment study (POTS) randomized controlled trial. JAMA, 292(16), 1969–1976. doi:10.1001/jama.292.16.1969CrossRef Google Scholar

Thomsen, P. H. (2004). Risperidone augmentation in the treatment of severe adolescent OCD in SSRI-refractory cases: A case-series. Annals of Clinical Psychiatry, 16(4), 201–207. doi:10.3109/10401230490522016CrossRef Google Scholar PubMed

Varigonda, A. L., Jakubovski, E., & Bloch, M. H. (2016). Systematic review and meta-analysis: Early treatment responses of selective serotonin reuptake inhibitors and clomipramine in pediatric obsessive-compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 55(10), 851–859. doi:10.1016/j.jaac.2016.07.768CrossRef Google Scholar PubMed

Book contents

19 - Pharmacologic-Augmented Treatments

Access options

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive